Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE – Get Free Report) saw unusually-high trading volume on Thursday . Approximately 1,711,463 shares changed hands during trading, an increase of 10% from the previous session’s volume of 1,552,051 shares.The stock last traded at $44.50 and had previously closed at $43.37.
Cerevel Therapeutics Price Performance
The firm has a 50-day simple moving average of $41.30 and a 200-day simple moving average of $41.80. The firm has a market cap of $8.09 billion, a P/E ratio of -16.21 and a beta of 1.40. The company has a current ratio of 10.22, a quick ratio of 10.22 and a debt-to-equity ratio of 0.60.
Cerevel Therapeutics (NASDAQ:CERE – Get Free Report) last issued its quarterly earnings data on Wednesday, May 8th. The biotechnology company reported ($0.73) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.61) by ($0.12). As a group, analysts forecast that Cerevel Therapeutics Holdings, Inc. will post -2.59 EPS for the current year.
Insider Transactions at Cerevel Therapeutics
Institutional Inflows and Outflows
Hedge funds have recently added to or reduced their stakes in the business. Headlands Technologies LLC acquired a new stake in Cerevel Therapeutics in the first quarter worth about $26,000. Pacific Capital Wealth Advisors Inc. purchased a new stake in Cerevel Therapeutics during the 4th quarter worth approximately $71,000. Centaurus Financial Inc. acquired a new position in Cerevel Therapeutics during the 4th quarter valued at approximately $119,000. Thurston Springer Miller Herd & Titak Inc. purchased a new position in shares of Cerevel Therapeutics in the second quarter worth $127,000. Finally, GAM Holding AG acquired a new stake in shares of Cerevel Therapeutics during the fourth quarter worth $212,000. 87.73% of the stock is owned by institutional investors and hedge funds.
About Cerevel Therapeutics
Cerevel Therapeutics Holdings, Inc, a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States. It is developing Emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures or focal epilepsy, as well as in phase 1 trial to treat panic symptoms model.
Recommended Stories
- Five stocks we like better than Cerevel Therapeutics
- How to Use Stock Screeners to Find Stocks
- Top 3 Small Cap Stocks Emerging as Rotation Winners
- Dividend Payout Ratio Calculator
- Bargain Alert: 3 Stocks Worth Watching While The Market Cools
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- Qualcomm Stock Could Be On The Verge of an Impressive Rally
Receive News & Ratings for Cerevel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerevel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.